Breaking News

Selvita Opens New Research Site in Poznan

February 4, 2016

Facility will be the first Selvita research site outside Krakow

Central and Eastern European drug discovery company, Selvita, has signed a contract for the lease of laboratory space in Poznan, Poland. The new site will be located at in the Wielkopolska Center of Advanced Technologies and begin research activities in the summer of 2016. The initial laboratory space will be 5,500 sq. feet, which constitutes a nearly 20% increase in Selvita laboratory space.

The Poznan facility will be the first Selvita research site outside Krakow.

At the beginning, Selvita plans to employ approximately 50 people in Poznan. Ultimately, the facility in Poznan is meant to be, according to the company, the “second heart of Selvita” providing both contract services, as well as actively participating in internal R&D projects.

“Wielkopolska region has a fantastic scientific potential. We are fully aware that for many talented graduates from local universities, the decision to relocate to Krakow can be very difficult, and for this reason we decided to come to them,” said Miroslawa Zydron, director of the contract chemistry department and member of the management board, Selvita. “The foundation of the Poznan team will be the employees coming from that region, who have already  been working  at Selvita for some time, in our laboratories in Krakow. Recently we have been also recruiting locally in Poznan. Selected candidates are being invited to join Selvita for a few months in Krakow, so they can have the opportunity to get to know our company and its organization, before they start working in Poznan.”

Selvita headquarters and the main laboratories with a research space of 30,000 sq. foot, are located in Krakow, Poland. In 2015, Selvita opened subsidiaries in major biotech centers around the world with Selvita Inc. in the greater Boston area and in the San Francisco Bay area in the U.S., and Selvita Ltd. in Cambridge, UK.
  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars